Adults receiving teprotumumab for the treatment of thyroid eye disease experience a similar number of hearing-related adverse events as those not treated with teprotumumab, according to new data.
As Healio previously reported, a small prospective cohort study found most adults who experience hearing loss after initiating teprotumumab-trbw (Tepezza, Amgen) had hearing dysfunction before starting the drug. New data published in The Journal of Clinical Endocrinology & Metabolism found the occurrence of hearing-related conditions was similar among those receiving teprotumumab as those not